Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Rubriques :
Maroc - HAEI.ORG - A La Une - 03/Sep 17:29
KalVista announces FDA acceptance of NDA for sebetralstat for oral on-demand treatment of HAE
KalVista announces FDA acceptance of New Drug Application for sebetralstat for oral on-demand treatment of hereditary angioedema KalVista Pharmaceuticals announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in [...]
Articles similaires
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025. Shares rise.
Intellia to present data from the Phase 2 study of NTLA-2002 for the treatment of HAE at the 2024 ACAAI Annual Scientific Meeting
Intellia Therapeutics to present data from the Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE) at the 2024 ACAAI Annual...
FDA extends review period for Medexus’ treosulfan to 2025
Medexus Pharmaceuticals (TSX:MDP) reveals the U.S. FDA has extended the review period for the company's new drug application for treosulfan.
FDA extends review period for Medexus’ treosulfan to 2025
Medexus Pharmaceuticals (TSX:MDP) reveals the U.S. FDA has extended the review period for the company's new drug application for treosulfan.
BioCryst presents new Orladeyo (berotralstat) data at 7th Bradykinin Symposium
BioCryst presents new Orladeyo (berotralstat) data at 7th Bradykinin Symposium BioCryst Pharmaceuticals today announced the presentation of six...
FDA Approves Ebglyss (lebrikizumab-lbkz) for the Treatment of Atopic Dermatitis
INDIANAPOLIS, Sept. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved...
Pharvaris provides business update and expands development program for deucrictibant
Pharvaris provides business update and expands development program for deucrictibant Pharvaris today announced: The planned initiation of CHAPTER-3,...
KalVista Presents Sebetralstat Data at Bradykinin Symposium 2024
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 KalVista Pharmaceuticals announced that it presented additional...
Les derniers communiqués
-
Aucun élément